Amarin (AMRN) Competitors $16.93 -0.39 (-2.25%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$16.62 -0.31 (-1.80%) As of 07/11/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRN vs. TVTX, CVAC, CALT, GPCR, AUPH, NAGE, AMPH, DYN, PAHC, and BGMShould you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Travere Therapeutics (TVTX), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), Aurinia Pharmaceuticals (AUPH), Niagen Bioscience (NAGE), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), Phibro Animal Health (PAHC), and BGM Group (BGM). These companies are all part of the "pharmaceutical products" industry. Amarin vs. Its Competitors Travere Therapeutics CureVac Calliditas Therapeutics AB (publ) Structure Therapeutics Aurinia Pharmaceuticals Niagen Bioscience Amphastar Pharmaceuticals Dyne Therapeutics Phibro Animal Health BGM Group Travere Therapeutics (NASDAQ:TVTX) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability. Do institutionals & insiders hold more shares of TVTX or AMRN? 22.3% of Amarin shares are held by institutional investors. 4.2% of Travere Therapeutics shares are held by insiders. Comparatively, 3.3% of Amarin shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, TVTX or AMRN? Travere Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Amarin has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Is TVTX or AMRN more profitable? Amarin has a net margin of -41.07% compared to Travere Therapeutics' net margin of -82.88%. Amarin's return on equity of -17.21% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-82.88% -1,179.73% -41.10% Amarin -41.07%-17.21%-12.16% Does the media prefer TVTX or AMRN? In the previous week, Travere Therapeutics had 2 more articles in the media than Amarin. MarketBeat recorded 4 mentions for Travere Therapeutics and 2 mentions for Amarin. Amarin's average media sentiment score of 1.32 beat Travere Therapeutics' score of 0.44 indicating that Amarin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amarin 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend TVTX or AMRN? Travere Therapeutics presently has a consensus price target of $32.14, suggesting a potential upside of 95.16%. Amarin has a consensus price target of $12.00, suggesting a potential downside of 29.12%. Given Travere Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Travere Therapeutics is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has better valuation & earnings, TVTX or AMRN? Amarin has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$233.18M6.27-$321.55M-$2.81-5.86Amarin$228.61M1.53-$82.18M-$3.64-4.65 SummaryTravere Therapeutics and Amarin tied by winning 8 of the 16 factors compared between the two stocks. Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRN vs. The Competition Export to ExcelMetricAmarinMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$358.64M$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.02%P/E Ratio-4.6520.5827.9620.25Price / Sales1.53292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book0.727.638.045.49Net Income-$82.18M-$55.05M$3.18B$250.27M7 Day Performance4.54%8.54%3.67%4.80%1 Month Performance26.53%5.51%4.09%7.68%1 Year Performance8.43%2.03%29.58%16.36% Amarin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRNAmarin0.3648 of 5 stars$16.93-2.3%$12.00-29.1%+13.5%$358.64M$228.61M-4.65360Gap UpTVTXTravere Therapeutics3.6152 of 5 stars$14.80+0.2%$32.14+117.2%+68.2%$1.31B$233.18M-5.27460CVACCureVac4.6825 of 5 stars$5.43+0.9%$6.83+25.8%+67.0%$1.22B$579.18M5.90880Positive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180GPCRStructure Therapeutics2.6129 of 5 stars$20.74-1.6%$76.17+267.2%-55.5%$1.19BN/A-23.84136AUPHAurinia Pharmaceuticals3.0457 of 5 stars$8.47-2.0%$11.50+35.8%+50.2%$1.14B$235.13M30.25300Positive NewsNAGENiagen Bioscience1.3362 of 5 stars$14.41+1.3%$19.50+35.3%N/A$1.14B$107.93M84.76120AMPHAmphastar Pharmaceuticals4.3237 of 5 stars$22.96-0.5%$32.33+40.8%-44.7%$1.08B$730.66M8.322,028DYNDyne Therapeutics3.4216 of 5 stars$9.52-0.5%$41.13+332.0%-79.4%$1.08BN/A-2.65100Analyst ForecastPAHCPhibro Animal Health4.0515 of 5 stars$25.54-0.5%$21.80-14.6%+76.0%$1.04B$1.02B32.741,940Gap UpBGMBGM GroupN/A$10.59-11.5%N/AN/A$1.03B$25.10M0.00298 Related Companies and Tools Related Companies Travere Therapeutics Alternatives CureVac Alternatives Calliditas Therapeutics AB (publ) Alternatives Structure Therapeutics Alternatives Aurinia Pharmaceuticals Alternatives Niagen Bioscience Alternatives Amphastar Pharmaceuticals Alternatives Dyne Therapeutics Alternatives Phibro Animal Health Alternatives BGM Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRN) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s whole-government AI plans leakedThe New Elon Musk is officially stepping back from his day-to-day duties with DOGE. At least, that's the s...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMRN Stock Alerts